financetom
Business
financetom
/
Business
/
Gautam Trivedi explains why he has a bias for private sector banks and is positive on defence, real estate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gautam Trivedi explains why he has a bias for private sector banks and is positive on defence, real estate
Jul 19, 2023 5:58 AM

Gautam Trivedi, the co-founder and managing partner at Nepean Capital, thinks the banking space still remains great. "They're not expensive. We continue to like that space. And I am, of course have a bias for private sector banks," he said while speaking to CNBC-TV18 on Wednesday.

Share Market Live

NSE

Trivedi also said that defence would be an area to focus on as a lot of orders are going to the defense companies. "Defence companies are finally getting their space in the sun. A lot of those orders are going to public sector defense companies. But I think a more of a private companies will also start to benefit," he noted.

"This is a promise, which I remember talking to even L&T, about eight, nine years ago, they had built up the whole infrastructure and were waiting for defense orders, which never really came. But finally, I think that's starting to happen," Trivedi said.

About the real estate space, he thinks there is there is a huge resurgence, as the sector has finally made a comeback after eight years. "And a company like Polycap and anybody within the building material space, is going to use the benefit, whether it's the ceramic companies, whether it's companies like Polycap, or even the Bajaj Electricals," he said.

Speaking on midcaps, Trivedi noted that the midcap space, unfortunately, has run up way ahead of its fundamentals and some of these valuations are very high. He said that he would wait for a correction and hopes that there is one in the market overall. "If that were to happen, I think I will focus on names like Polycab or some of the ceramic companies," he added.

On telecom, he said: "We haven't bought Bharti Airtel. It's the only listed play as of now. Jio is not listed and Vodafone of course it is a crapshoot if that's going to survive. And MTNL, I guess the government has thrown in the towel. So Bharti is the only one that's really left standing from a listed play in the way to play the mobile telecom play. But having said that, I think the EMS companies are what we like, as I just mentioned, there's going to be huge potential there."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BigBear.ai Says it Gets US Navy's SeaPort NxG Contract for Systems Engineering, Process Engineering
BigBear.ai Says it Gets US Navy's SeaPort NxG Contract for Systems Engineering, Process Engineering
Jan 30, 2025
10:29 AM EST, 01/30/2025 (MT Newswires) -- BigBear.ai Holdings ( BBAI ) said Thursday it has received an indefinite delivery/indefinite quantity contract under the US Department of Navy's SeaPort Next Generation program to offer systems engineering, process engineering and specialized technology services. Financial terms were not disclosed. Shares of the company rose 12% in recent Thursday trading. Price: 4.08, Change:...
--Sandy Spring Bancorp Keeps Quarterly Dividend at $0.34 a Share, Payable Feb. 19 to Shareholders as of Feb. 12
--Sandy Spring Bancorp Keeps Quarterly Dividend at $0.34 a Share, Payable Feb. 19 to Shareholders as of Feb. 12
Jan 30, 2025
10:29 AM EST, 01/30/2025 (MT Newswires) -- Price: 33.87, Change: +0.40, Percent Change: +1.20 ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk says it has not yet posted details about new CagriSema trial
Jan 30, 2025
LONDON, Jan 30 (Reuters) - Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data in December disappointed the market. Reuters reported earlier on Thursday that the Danish drugmaker will launch a new Phase III trial of the...
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors
Jan 30, 2025
10:29 AM EST, 01/30/2025 (MT Newswires) -- Pacific Biosciences of California ( PACB ) said Thursday it has appointed Chris Smith, chief executive of NeoGenomics ( NEO ) , to the board of directors, effective immediately. Smith has extensive experience in the life sciences and healthcare industries and led growth and innovation at NeoGenomics ( NEO ) in precision medicine,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved